Immunglobuline-Reference-Cited by-同舟云学术

Immunglobuline

Published:2015-11-11 Issue: Volume: Page:231-237
ISSN:
Container-title:Sepsis und MODS
language:
Short-container-title:

Author:

Werdan K.

Publisher

Springer Berlin Heidelberg

Link

http://link.springer.com/content/pdf/10.1007/978-3-662-45148-9_16

Reference26 articles.

1. Alejandria MM, Lansang MAD, Dans LF, Mantaring III JB (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database 9 [Aktuellste Metaanalyse, welche die Ergebnisse von ivIgG- und ivIgGMA-Studien getrennt ausgewertet hat.] ←

2. Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, Tartamella F, Prisco L, Bigotto F, Bigolin T, Ferluga M, Batticci I, Michelone E, Borelli M, Viviani M, Tomasini A (2012) Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: A retrospective analysis. J Crit Care 27(2): 167–171

3. Bermejo-Martin JF, Rodriguez-Fernandez A, Herrán-Monge R, Andaluz-Ojeda A, Muriel-Bombin A, Merono P, Garcia-Garcia MM, Citores R, Gandia F, Almansa R, Blanco J; for the GRECIA Group (Grupo de Estudios y Analisis en Cuidados Intensivos) (2014) Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Int Med 276: 404–412

4. Brunner R, Rinner W, Haberler C, Kitzberger R, Sycha T, Herkner H, Warszawska J, Madl C, Holzinger U (2013) Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial. Crit Care 17: R213

5. Bundesärztekammer (2015) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Kap 9. Humane Immunglobuline. Deutscher Ärzteverlag, Köln, 4. aktualisierte und überarbeitete Auflage, pp 201–226